Baxter receives CE Mark approval for Homechoice Claria APD system

Baxter has announced that its new Homechoice Claria automated peritoneal dialysis (APD) system has received CE Mark approval, ahead of a planned European launch in the first half of 2015.

The new APD device has been designed to offer user-friendly features and secure two-way connectivity, providing increased visibility over patient home peritoneal dialysis data that allows clinicians to adjust prescriptions as necessary.

It is integrated with the Sharesource web-based connectivity platform, which gathers patient and clinical data into organised report dashboards. This eliminates the need for unnecessary data entry, saving time and enhancing efficiency.

Other advantages of the new system include its large, two-line display screen for better visibility, and its universal interface available in 41 languages.

Dr Bruce Culleton, vice-president and renal therapeutic area lead at Baxter, said: "Claria builds upon our market-leading Homechoice APD device with new features to make the system more intuitive for patients to operate in their home and while travelling."

Baxter will be refining its focus on medical technology and life science innovations once it completes the planned spinoff of its pharmaceutical division into a standalone business called Baxalta.